ABSTRACT
Background: hypertriglyceridemia, in combination with low HDL cholesterol levels, is a risk factor for cardiovascular disease. Our objective was to evaluate the efficacy of Ciprofibrate for the treatment of this form of dyslipidemia and to identify factors associated with better treatment response
Methods: multicenter, international, open-label study. Four hundred and thirty seven patients were included. The plasma lipid levels at inclusion were fasting triglyceride concentrations between 1.6 - 3.9 mM/L and HDL cholesterol ?1.05 mM/L for women and ?0.9 mM/L for men. The LDL cholesterol was below 4.2 mM/L. All patients received Ciprofibrate 100 mg/d. Efficacy and safety parameters were assessed at baseline and at the end of the treatment. The primary efficacy parameter of the study was percentage change in triglycerides from baseline
Results: after 4 months, plasma triglyceride concentrations were decreased by 44% [p <0.001]. HDL cholesterol concentrations were increased by 10% [p < 0.001]. Non-HDL cholesterol was decreased by 19%. A greater HDL cholesterol response was observed in lean patients [body mass index <25 kg/m2] compared to the rest of the population [8.2 vs 19.7%, p <0.001]. In contrast, cases with excess body weight had a larger decrease in non-HDL cholesterol levels [-20.8 vs -10.8%, p <0.001]. There were no significant complications resulting from treatment with Ciprofibrate
Conclusions: ciprofibrate is efficacious for the correction of hypertriglyceridemia/low HDL cholesterol. A greater decrease in non-HDL cholesterol was found among cases with excess body weight. The mechanism of action of Ciprofibrate may be influenced by the pathophysiology of the disorder being treated